Clinical Trials Logo

Tracheal Stenosis clinical trials

View clinical trials related to Tracheal Stenosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05153668 Active, not recruiting - Clinical trials for Idiopathic Subglottic Tracheal Stenosis

Everolimus Trial in Laryngotracheal Stenosis

Start date: September 30, 2022
Phase: Early Phase 1
Study type: Interventional

Subglottic stenosis (obstructing scar in the larynx and trachea) occurs in patients spontaneously (idiopathic), with autoimmune disease, and after long-term breathing tube placement and can result in communication disability and high mortality rates due to the obstructed airway. The proposed Adjuvant EveRolimus Outcomes (AERO) trial is proof-of-concept study using the immunosuppressant drug, everolimus, to reduce the number of surgeries for patients with idiopathic Subglottic Stenosis (iSGS). Success with the AERO trial will allow for everolimus to be used in subsequent larger trials of participants with laryngotracheal stenosis and could lead to everolimus being the first FDA approved medical treatment for iSGS.